PTCT PTC THERAPEUTICS, INC.
Price Chart
Executive Summary
Two insiders at PTC Therapeutics sold a combined $220K of stock shortly after a strong Q1 earnings beat and raised guidance. CEO Matthew Klein's sale is a routine tax-withholding grant (12,500 shares awarded, none sold), while General Counsel Mark Boulding exercised options and sold a portion of the resulting shares. The total dollar value is only ~0.004% of market cap—immaterial and likely driven by standard post-earnings window openings and tax-planning, not a bearish signal.
Key Financial Metrics
Actionable Insight
This cluster is noise. The post-earnings window and strong fundamentals (raised guidance, Sephience momentum) continue to support PTCT. Monitor if larger C-suite sales emerge in the next 30 days, but this filing alone carries no bearish conviction.
Key Facts
- CEO Matthew Klein: 12,500 shares granted via award ($0) on May 13; then sold 679 shares at $73.06 ($50K) on May 14—a small tax-coverage disposition.
- General Counsel Mark Boulding: exercised 5,624 options (2,812 at $0, 2,812 at $25.69) on May 15; sold 2,356 shares ($170K) open-market.
- Total insider sales value ~$220K, representing ~0.004% of PTCT's $5.8B market cap.
- Just 12 days prior, PTCT reported Q1 2026 product revenue of $226M (up 47% YoY) and raised full-year product revenue guidance to $750-$850M.
- The insider cluster occurred after a strong earnings report and within an open trading window—consistent with routine post-earnings option exercises and tax sales.
Financial Impact
Insider sales of ~$220K — negligible relative to $5.8B market cap
Risk Factors
- Translarna and Emflaza revenue continue to decline due to generic erosion and regulatory headwinds.
- Any future insider sales above ~$2M (0.03% of market cap) would be more notable, especially if from CEO or CFO.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTCT-1779225646329 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
8-K
| $73.75 awaiting T+5 | awaiting T+5 | — | $70.87 (−3.91%) |
|
May 19, 2026
21d ago
|
Insider Cluster
| $71.02 $71.05 | ▲ +0.04% | ▼ −1.76% | $70.87 (−0.21%) |
|
May 15, 2026
25d ago
|
Insider Cluster
| $70.15 $67.65 | ▼ −3.56% | ▼ −5.18% | $70.87 (+1.03%) |
|
Apr 28, 2026
6w ago
|
8-K
| $64.55 $66.57 | ▲ +3.13% | ▲ +0.02% | $70.87 (+9.79%) |
|
Apr 20, 2026
7w ago
|
DEFA14A
| $70.63 $70.26 | ▼ −0.52% | ▼ −1.61% | $70.87 (+0.34%) |
|
Apr 1, 2026
10w ago
|
Insider Cluster
| $68.75 $70.85 | ▼ −3.05% | ▲ +0.71% | $70.87 (−3.08%) |
|
Mar 5, 2026
13w ago
|
Insider Cluster
| $63.33 $63.36 | ▲ +0.05% | ▲ +2.29% | $70.87 (+11.91%) |
|
Mar 5, 2026
13w ago
|
Insider Cluster
| $63.33 $63.36 | ▼ −0.05% | ▼ −2.29% | $70.87 (−11.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access